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In this video Q&A, Mr Mike Carmont answers questions about state-of-the-art treatments for elite athletes, and the
progress and challenges behind translating these into successful therapies for the non-elite athlete.Introduction
I am a consultant trauma and orthopaedic surgeon with
an interest in sports medicine. I think, looking back, my
first interest in sports medicine started when I submitted
a presentation to the first Consensus Meeting for Con-
cussion in Sport in Zurich - that was over 12 years ago. I
was attracted to the demonstration of the interaction of
science, medicine and sport. After that, I went to the
2002 Commonwealth Games where I was an event-side
doctor at the field of play and saw some sports practice
in action. Since then, I’ve been attracted to the precision
and accuracy of the sports surgery techniques through-
out my orthopaedic training, and that’s something that I
continue in my current practice. I am currently the
President of the British Orthopaedic Sports Trauma and
Arthroscopy Association.
Transcript
1. As an orthopaedics surgeon, does your treatment of
athletes differ from your treatment of those not involved
in sports?
Not really. All the patients I treat are treated the same
way. I try to use the best evidence I have from the litera-
ture and I discuss the treatment options of any parti-
cular problem. We have to remember that the patients
themselves choose which procedure they wish to have
performed, and they need to understand the outcomes
of the treatment selected. A typical case of this would
be meniscal injury. Many years ago, it was thought
the meniscus was a vestigial structure in the knee, andCorrespondence: mcarmont@hotmail.com
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2014following a tear, these would just be removed. But now we
know the importance of the meniscus for loading, stability
and proprioception, and nutrition within the knee. We
now know that a meniscectomy does lead to arthritis.
Meniscal repair is not 100% successful, but in the majority
of cases, it does lead to a good recovery. That allows our
patients to return to sports and activity with less of a risk
of the onset of arthritis as a result of their tear.2. When treating elite athletes, do you ever have to
compromise long-term health outcomes for short-term
sports performance gains?
No, I try as best I can to manage all my patients the
same. I try and promote physical activity for all patients.
It’s very important when managing the social, recrea-
tional and elite or professional athletes. I try and use
standard, best evidence and well-researched techniques
where possible to improve outcome.3. In terms of surgery for the athlete, have there been
any advances within the past few years that could
potentially allow that athlete to return to the same form
pre-injury?
Anterior cruciate ligament (ACL) injuries are one of
the most common knee injuries. It tends to occur in a
young, sporting population during sport, particularly
ones that involve a cut or plant, or a sudden change in
direction, particularly in popular sports such as football
and skiing. Whereas people with these injuries may be
able to adopt normal activities of daily living, the ab-
sence or tear of this ligament mean that they may not be. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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consequence give up these sports.
The surgery for ACL is fascinating. The techniques
have evolved over the past two decades. Whereas ori-
ginally surgeons were performing trans-tibial techniques
to try and replace and reconstruct the ligament across
the knee, now they are trying to restore a more natural
and anatomical appearance to the reconstruction, with
the use of double-bundle and more anatomical single-
bundle techniques. This is one of the key components of
sports surgery. One has to ascertain whether these tech-
niques themselves are an improvement - that is one of
the significant challenges. We need to have very accurate
outcome scores and assessments, and it could be that
the small improvements that are made are not deter-
mined and evaluated by the outcome measurements
we have. For instance, for the more anatomical single-
bundle ACL reconstructions, some groups have suggested
that these may be more prone to tearing and have a higher
re-rupture rate. This could be because the knee is more
restrained and adopts a more natural position, and that
the reconstructed tissue has a greater load than the tissue
placed elsewhere in the knee.4. Are there any advantages in ACL repair versus ACL
reconstruction?
That’s another interesting development. Over the past
few years, people have reflected back to the considera-
tion of repairing the torn ACL, rather than reconstruc-
ting it. Here, the body has its own tissue put back in the
natural place. But we have to remember that this tissue
has strained and then ultimately failed before reattach-
ment, and so the procedure is very difficult to do. With
the use of scaffolds and matrices put inside the knee,
this is something that will become increasingly common
in the next decade. Science will show us if this is an im-
provement or not.
5. Have there been any advances in sports surgery in the
elite athlete that have translated into treatment options
for the non-athlete and recreational athlete. For example,
with platelet-rich plasma?
Platelet-rich plasma (PRP) is the concept where you take
someone’s whole blood, place it into a centrifuge, and
spin it out into it component products. You can then
take a small amount of the serum which is rich in
growth factors, which has biological factors to promote
healing and enhance recovery. You’d then re-inject this
into the athlete into an area of, for example, degenera-
tive tissue. Classic problems for this would be tendino-
pathy, or enthesopathies such as lateral epicondylitis,
and also Achilles tendinopathy. These are very difficult
problems to treat and they are also reasonably common
in the general population.
6. Are there any challenges in comparing treatments
tested in elite athletes for translation into the non-
athlete?
Elite athletes are a difficult group to compare - they’ll
use any technique to get them back to return to play.
This may well mean that, in terms of their overall return
to activity, they are harder to follow and not directly
comparable to the general population. This is because
the elite athlete will have better physiotherapy, treatment
modalities and better rehabilitation techniques, and also
better motivation, too. So the outcomes in elite athletes
are possibly not comparable to the general population.
7. What is the current evidence supporting the use of PRP?
There have been a number of studies which have looked
at these, and it’s very hard to show that the administra-
tion of these techniques shows a definite difference in a
randomized prospective study.
For instance, at the elbow, Mishra from California has
reported significant improvement in visual analogue
scores for pain (P = 0.02); [at 24 weeks with PRP in a
double-blind prospective randomized study on 230 patients
with chronic tennis elbow]. However, when compared in
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of PRP and glucocorticoids, they showed no significant
benefits of any of the treatment arms of the PRP com-
pared to the placebo arms.
Achilles tendinopathy is another common problem.
Susan de Jonge’s group in the Netherlands have put a lot
of work into this, and they found that tendinopathy is
very common; between two and three of every 1,000
members of the Dutch population will have Achilles ten-
dinopathy. It is a very troublesome problem - it’s chronic.
The same research group have looked at the overall out-
come, and five years after all treatments, 40% of people
will still have levels of pain and dysfunction. Yes, their
symptoms may have improved, but they will no longer be
pain-free as a result of their problem.
Various studies have looked at the use of PRP versus
the use of placebo concurrently with eccentric loading
exercises, and these haven’t shown a significant benefit.
The tendon structure has improved and you get a more
natural appearance of the tendon, and it’s thought that
it’s the loading exercises which are achieving this. Con-
versely, across the Atlantic, Owens’ group showed a
modest improvement. So, it can be very difficult to tell if
it is the PRP which is making a difference, which is why
we do need to have randomized and prospective con-
trolled studies to try and resolve these issues.
8. Where can I find out more?
See references [1-15].
Additional file
: Mike Carmont discusses state-of-the-art therapy
for the elite and non-elite athlete.
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